The year 2025 closes as one of the most transformative periods in contemporary medical research. Driven by the convergence of advanced biotechnology, artificial intelligence, and personalized medicine, biomedical science has achieved milestones that just a decade ago seemed like science fiction. From gene editing designed for a single patient to advances in tissue regeneration that mimic salamanders, earlier cancer diagnoses, and new strategies against HIV, this year's progress anticipates a structural shift in how diseases are prevented, diagnosed, and treated. Despite a context marked by budget cuts in several countries, the international scientific community has demonstrated an extraordinary capacity for innovation that is redefining the limits of what is possible in medicine. Personalized Gene Editing: In February, the Children's Hospital of Philadelphia achieved an unprecedented milestone: the first CRISPR gene-editing therapy tailored for a single patient, an infant with a life-threatening metabolic disorder. Doctors designed a custom gene that was delivered to the baby's liver using lipid nanoparticles, allowing them to correct the genetic defect. The result was extraordinary: the child's dependence on medication was significantly reduced, and his quality of life improved. By November, the baby's mother reported that he had started walking and was meeting other developmental milestones. This advance represents a qualitative leap for CRISPR-Cas9 technology, whose developers won the Nobel Prize in 2020, indicating that other patients with genetic disorders could benefit from this technology in the future. Interfering with pancreatic cancer before it appears: With a survival rate of less than 13%, pancreatic cancer is one of the deadliest. Researchers achieved a promising breakthrough by discovering that blocking the FGFR2 protein, which accelerates the growth of early-stage pancreatic cancer cells,It prevents them from becoming cancerous in certain situations. The studies were conducted on laboratory mice and human cells.

The most hopeful aspect is that drugs already exist that can inhibit this protein, so researchers plan to test this approach in high-risk individuals, especially those with a family history of the disease. }

Regeneration in Humans

One of the most fascinating fields of the year was regenerative medicine. Scientists studying how amputee salamanders regenerate their limbs identified an enzyme that adjusts the levels of retinoic acid, a molecule essential for regeneration. They also identified a gene that controls the size and development of the appendages.

Since humans possess the same molecular components, these findings offer a blueprint that could one day guide limb regeneration in people recovering from traumatic injuries. In addition, scientists from Harvard University and the Gladstone Institute have developed implantable heart patches and functional ureteral tissue from human stem cells, bringing us closer to the possibility of rebuilding damaged organs and tissues.

Xenotransplantation: Pig Organs for Humans

Massachusetts General Hospital successfully transplanted a genetically modified pig liver into a human patient, who survived 171 days with the organ and demonstrated its functionality. The patient, a 71-year-old man with liver disease caused by hepatitis B and liver cancer, was ineligible for a human liver or conventional surgery.

This result represents a crucial step toward using animal organs to alleviate the shortage of human donors, a problem affecting thousands of patients on waiting lists worldwide.

Hormone-Free Treatments for Menopause

Two new non-hormonal treatments for moderate to severe hot flashes now offer relief to those who previously had no options. The US FDA approved Lynkuet (elinzanetant) in October, joining Veozah (fezolinetant), approved two years earlier. These daily pills act on temperature-regulating neurons in the brain's hypothalamus, after scientists discovered that these nerve cells are susceptible to estrogen fluctuations during menopause. The European Medicines Agency also approved elinzanetant in December, expanding options for millions of women with contraindications to traditional hormone therapy. HIV Prevention: Long-Acting Prophylaxis The introduction of long-acting pre-exposure prophylaxis (PrEP),With injectable drugs administered only twice a year, it promises to improve adherence and significantly reduce transmission. This advance represents a milestone in HIV prevention, as previously patients had to take daily medication.

At the same time, new research on HIV vaccines is being driven by computational models and artificial intelligence tools that allow for faster and more precise identification of immunological targets.

mRNA Vaccines Beyond COVID

Vaccines using messenger RNA technology, which became known during the pandemic, are now being tested in hundreds of clinical trials against influenza, HIV, cardiovascular diseases, and various types of cancer. Institutions such as the WHO and the US National Institutes of Health closely monitored the studies, whose preliminary results show the ability of these vaccines to induce neutralizing antibodies and improve the immune response. Furthermore, lung and skin cancer patients treated with immunotherapy responded better and lived longer if they had received the mRNA vaccine against COVID-19 before their treatment, suggesting that activation of the immune system enhances other cancer therapies. AI Efficacy in Diagnosis: AI systems have demonstrated high accuracy in diagnosing pathologies such as skin cancer, brain tumors, cardiovascular diseases, and lung conditions, and are being progressively integrated into routine hospital practice. AI can analyze medical images such as X-rays and MRIs to detect cancer, diabetic retinopathy, and Alzheimer's with high accuracy. Furthermore, AI platforms applied to drug discovery have drastically reduced development times, allowing therapeutic candidates to be identified in weeks instead of years. AI also excels in personalized medicine, tailoring treatments to each patient's genetic profile and medical history.

Obstructive Sleep Apnea Pill Just Around the Corner

Following a late-stage clinical trial showing positive results, the first oral pill for obstructive sleep apnea (OSA) could be available soon, according to pharmaceutical company Apnimed Inc.

The drug AD109 showed “clinically significant and statistically significant reductions” in airway obstruction after 26 weeks, the company said in a press release.

Unprecedented Atlas of the Human Body

British researchers have completed more than one billion medical scans of 100,000 volunteers, creating an unprecedented atlas of the human body.

This massive biobank provides an invaluable database for understanding human variability, identifying early disease markers, and developing more precise treatments.

You may also be interested in: